Advance Clinical Trials and Research

Biomarkers&Biomarker Discovery and Drug Development

Although there are numerous crucial applications for biomarkers in clinical practise and product testing, most of them have not been proven to accurately predict clinical outcomes. Several of these case studies demonstrate how promising phase 2 biomarker data does not always transfer into successful product performance. Phase 2 testing of medications for disorders including AD (semagacestat), cardiac disease (aliskiren, darapladib, torcetrapib), Staph infection (V710 vaccine), and herpes infection (herpes simplex) revealed positive biomarker results (HSV-2 vaccine). In phase 3 trials, these investigational goods were not shown to be productive.

The process of creating a new medicine can be difficult and require a number of intricate steps. Every stage of the drug development process, including the initial identification of potential drugs, translational research, clinical development, and reverse translational studies, requires the use of well-validated biomarkers in order to avoid costly errors.

Through all of these phases, effective biomarker discovery and validation are made possible by NanoString's systems. No matter what kind of spatial analysis your research calls for—bulk, single-cell, or sub-cellular—our cutting-edge technology can hasten your scientific findings in the field of drug development.